BofA Securities Downgrades Tyra Biosciences (TYRA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TYRA Hot Sheet
Price: $21.37 --0%
Rating Summary:
15 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
15 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham downgraded Tyra Biosciences (NASDAQ: TYRA) from Buy to Neutral with a price target of $15.00 (from $25.00).
For an analyst ratings summary and ratings history on Tyra Biosciences click here. For more ratings news on Tyra Biosciences click here.
Shares of Tyra Biosciences closed at $14.78 yesterday.
You May Also Be Interested In
- Goldman Sachs Downgrades United Overseas Bank Ltd. (UOB:SP) (UOVEY) to Sell
- Astera Labs (ALAB) PT Lowered to $300 at TD Cowen
- Waters Corp. (WAT) PT Raised to $535; Bernstein SocGen: 'Low bar, high upside'
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
